Acquired Hemophilia News and Research

RSS
Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Inspiration, Ipsen and Baxter enter Asset Purchase Agreement for OBI-1

Inspiration, Ipsen and Baxter enter Asset Purchase Agreement for OBI-1

Interim results from Inspiration’s OBI-1 and IB1001 hemophilia clinical study

Interim results from Inspiration’s OBI-1 and IB1001 hemophilia clinical study

Inspiration, Ipsen receive FDA Fast Track designation for OBI-1 to treat AHA

Inspiration, Ipsen receive FDA Fast Track designation for OBI-1 to treat AHA

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A

Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A

Ipsen, Inspiration partner to launch hemophilia product portfolio in Europe

Ipsen, Inspiration partner to launch hemophilia product portfolio in Europe

Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress

Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration presents IB1001 PK data for treatment of hemophilia B

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen and Inspiration Biopharmaceuticals form strategic partnership

Ipsen and Inspiration Biopharmaceuticals form strategic partnership

FDA approves new formulation of genetically engineered version of Factor VIIa plasma protein

FDA approves new formulation of genetically engineered version of Factor VIIa plasma protein